On Tuesday, June 24, 2014 ProMedica Laboratories will offer improved Antiphospholipid testing to aid in the diagnosis of SLE and SLE-like disorders. This testing will include Anticardiolipin Antibody testing (IgG, IgM & IgA) and Beta-2 Glycoprotein 1 testing (IgG, IgM & IgA). The test code will be ACA for the Anticardiolipin Antibodies and B2G for the Beta-2 Glycoproteins. These assays will be performed on an automated random access analyzer and can, therefore, be performed daily. We look forward to the opportunity to improve the turn-around time of these tests to aid physicians in their diagnosis.

These assays have increased sensitivity and specificity in order to minimize the risk of false positive results. The assays were set to the 99th percentile of a normal healthy population, with each test having a cutoff of 20 units.

The revised Sapporo Classification Criteria for laboratory results when diagnosing Antiphospholipid Syndrome (APS) include:

1. Lupus Anticoagulant present on two or more occasions at least 12 weeks apart
2. Anticardiolipin IgG and/or IgM antibodies in a medium to high level (>40 units, respectively) on two or more occasions at least 12 weeks apart
3. Anti-Beta 2 glycoprotein 1 antibodies IgG and/or IgM present in two or more occasions at least 12 weeks apart

Measurement of Anticardiolipin IgA and Beta-2 glycoprotein 1 IgA may enable clinicians to identify additional patients with clinical suspicion of APS who do not meet the current diagnostic criteria, when other IgG & IgM levels are negative but APS is highly suspected.

For additional information, please contact ProMedica Laboratories Customer Service at 419-291-4134.